1. Signaling Pathways
  2. Apoptosis
  3. TNF Receptor

TNF Receptor (肿瘤坏死因子)

Tumor Necrosis Factor Receptor; TNFR

肿瘤坏死因子 (TNF) 是细胞凋亡以及炎症和免疫的主要介质,并且与多种人类疾病的发病机制有关,包括败血症、糖尿病、癌症、骨质疏松症、多发性硬化症、类风湿性关节炎和炎症性肠病。

TNF-α 是一种 17 kDa 蛋白质,由 157 个氨基酸组成,在溶液中为同源三聚体。在人类中,该基因位于 6 号染色体上。其生物活性主要受可溶性 TNF-α 结合受体的调节。TNF-α 主要由活化的巨噬细胞、T 淋巴细胞和自然杀伤细胞产生。已知多种其他细胞的表达较低,包括成纤维细胞、平滑肌细胞和肿瘤细胞。在细胞中,TNF-α 合成为 pro-TNF (26 kDa),它与膜结合,在 TNF 转换酶 (TACE) 裂解其 pro 结构域后释放。

许多 TNF 诱导的细胞反应是由两种 TNF 受体 TNF-R1 和 TNF-R2 中的任一种介导的,这两种受体都属于 TNF 受体超家族。在 TNF 治疗后,转录因子 NF-κB 和 MAP 激酶(包括 ERK、p38 和 JNK)在大多数类型的细胞中被激活,在某些情况下,也可能诱导细胞凋亡或坏死。然而,诱导细胞凋亡或坏死主要是通过 TNFR1 实现的,TNFR1 也称为死亡受体。NF-κB 和 MAPK 的激活在多种细胞因子和免疫调节蛋白的诱导中起着重要作用,并且对许多炎症反应至关重要。

Tumor necrosis factor (TNF) is a major mediator of apoptosis as well as inflammation and immunity, and it has been implicated in the pathogenesis of a wide spectrum of human diseases, including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.

TNF-α is a 17-kDa protein consisting of 157 amino acids that is a homotrimer in solution. In humans, the gene is mapped to chromosome 6. Its bioactivity is mainly regulated by soluble TNF-α–binding receptors. TNF-α is mainly produced by activated macrophages, T lymphocytes, and natural killer cells. Lower expression is known for a variety of other cells, including fibroblasts, smooth muscle cells, and tumor cells. In cells, TNF-α is synthesized as pro-TNF (26 kDa), which is membrane-bound and is released upon cleavage of its pro domain by TNF-converting enzyme (TACE).

Many of the TNF-induced cellular responses are mediated by either one of the two TNF receptors, TNF-R1 and TNF-R2, both of which belong to the TNF receptor super-family. In response to TNF treatment, the transcription factor NF-κB and MAP kinases, including ERK, p38 and JNK, are activated in most types of cells and, in some cases, apoptosis or necrosis could also be induced. However, induction of apoptosis or necrosis is mainly achieved through TNFR1, which is also known as a death receptor. Activation of the NF-κB and MAPKs plays an important role in the induction of many cytokines and immune-regulatory proteins and is pivotal for many inflammatory responses.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-11109
    Resatorvid

    瑞沙托维

    Inhibitor 99.95%
    Resatorvid (TAK-242) 是一种选择性的 TLR4 信号传导抑制剂。Resatorvid 抑制 NOTNF-αIL-6 的产生,其 IC50 值分别为 1.8 nM,1.9 nM,1.3 nM。Resatorvid 下调 TLR4 下游信号分子 MyD88 和 TRIF 的表达。Resatorvid 抑制自噬 (autophagy),并在各种炎症性疾病中起关键作用。
    Resatorvid
  • HY-N0822
    Shikonin

    紫草素

    Inhibitor 99.80%
    Shikonin 是中草药紫草的主要成分。Shikonin 是一种有效的 TMEM16A 氯化物通道 (chloride channel) 抑制剂,IC50 为 6.5 μM。Shikonin 是一种特异的丙酮酸激酶 M2 (PKM2) 抑制剂,还可以抑制 TNF-αNF-κB途径。Shikonin 通过抑制糖酵解降低外泌体 (exosome) 的分泌。Shikonin 抑制 AIM2炎性体活化。
    Shikonin
  • HY-P9970
    Infliximab

    英夫利昔单抗

    Inhibitor
    Infliximab (Avakine) 是一种与 TNF-α 特异性结合的嵌合单克隆 IgG1 抗体。Infliximab 可阻止 TNF-α 与 TNF-α 受体 1 (TNFR1) 和 TNFR2 的相互作用。Infliximab 可用于自身免疫,慢性炎症性疾病和糖尿病神经病变的研究。
    Infliximab
  • HY-N0182
    Fisetin

    漆黄素

    Inhibitor 99.99%
    Fisetin是一种在许多水果和蔬菜中发现的天然黄酮醇,具有多种益处,如抗氧化,抗癌,神经保护作用。
    Fisetin
  • HY-P9908
    Adalimumab

    阿达木单抗

    Inhibitor 99.62%
    Adalimumab 是一种人源的单克隆 IgG1 抗体,靶向肿瘤坏死因子α (TNF-α)。
    Adalimumab
  • HY-P99909
    Elranatamab

    埃纳妥单抗

    Elranatamab (PF-06863135) 是一种抗 CD3E/TNFRSF17 的人源 IgG2κ 单克隆抗体。Elranatamab 的同型对照产品:Human IgG2 kappa, Isotype Control (HY-P99002)。
    Elranatamab
  • HY-P9970A
    Infliximab (Anti-TNF-α)

    英夫利昔单抗 (Anti-TNF-α)

    Inhibitor 99.00%
    Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) 是一种与 TNF-α 特异性结合的嵌合单克隆 IgG1 抗体。Infliximab (Anti-TNF-α) 可阻止 TNF-α 与 TNF-α 受体 1 (TNFR1) 和 TNFR2 的相互作用。Infliximab (Anti-TNF-α) 可用于自身免疫,慢性炎症性疾病和糖尿病神经病变的研究。
    Infliximab (Anti-TNF-α)
  • HY-P990876
    Afimkibart 99.34%
    Afimkibart (PF-06480605) 是一种人 IgG1 单克隆抗体,靶向肿瘤坏死因子样配体 1A (TL1A)。Afimkibart 可用于炎症性肠病的研究。
    Afimkibart
  • HY-108847
    Etanercept

    依那西普

    Inhibitor 99.20%
    Etanercept 是一种结合肿瘤坏死因子 (TNF) 的二聚体融合蛋白,作为 TNF 抑制剂。Etanercept 竞争性地抑制 TNF-α 和 TNF-β 与细胞表面 TNF 受体的结合,使肿瘤坏死因子在生物学上失去活性。Etanercept 对风湿性关节炎、幼年特发性关节炎和斑块性银屑病有效。
    Etanercept
  • HY-P0224
    N-Formyl-Met-Leu-Phe Inhibitor 99.36%
    N-Formyl-Met-Leu-Phe (fMLP; N-Formyl-MLF) 是一种趋化肽和N-甲酰基肽受体 (FPR) 的特异性配体。报道显示N-Formyl-Met-Leu-Ph 可抑制 TNF-alpha 的分泌。
    N-Formyl-Met-Leu-Phe
  • HY-107632
    GYY4137 Inhibitor 98.08%
    GY4137 是一种缓释 H2S 供体,具有血管扩张、抗高血压活性和抗炎活性。 GY4137 能通过阻断 STAT3 通路,从而抑制细胞生长、诱导了细胞凋亡 (apoptosis) 和细胞周期停滞,表现出强效的抗癌活性。
    GYY4137
  • HY-N0262
    Cordycepin

    虫草素

    99.43%
    Cordycepin (3'-Deoxyadenosine) 是一种核苷衍生物,在类风湿性关节炎滑膜成纤维细胞 (RASF) 中,抑制 IL-1β 诱导的 MMP-1MMP-3 表达,这种作用存在剂量依赖性。Cordycepin 通过抑制细菌的腺苷激酶杀死结核分枝杆菌。
    Cordycepin
  • HY-12085
    Apremilast

    阿普司特

    Inhibitor 99.91%
    Apremilast (CC-10004) 是一种口服有效的磷酸二酯酶 4 (PDE4) 抑制剂,IC50 为 74 nM。Apremilast 抑制脂多糖 (LPS) 释放 TNF-α,IC50 为 104 nM。
    Apremilast
  • HY-110203
    R-7050 Antagonist 98.55%
    R-7050 (TNF-α Antagonist III) 是一种肿瘤坏死因子受体 (TNFR) 拮抗剂,对 TNFα 具有更高选择性。
    R-7050
  • HY-N0136
    Taxifolin

    二氢槲皮素

    99.92%
    Taxifolin ((+)-Dihydroquercetin) 具有重要的抗酪氨酸酶活性。Taxifolin 有效抑制胶原酶 (collagenase),IC50 为 193.3 μM。Taxifolin是一种重要的天然化合物,具有抗纤维化作用。Taxifolin 是一种自由基清除剂具有抗氧化能力。
    Taxifolin
  • HY-P1860
    TNF-α (31-45), human Activator 99.77%
    TNF-α (31-45), human 是一种有效的 NF-kB 通路激活剂,也是一种促炎细胞因子,可诱导坏死或凋亡。TNF α 通过 TNFR2 刺激 NF-κB 通路,促进癌症生长、侵袭和转移。
    TNF-α (31-45), human
  • HY-B0809
    Theophylline

    茶碱

    Inhibitor 99.89%
    Theophylline (1,3-Dimethylxanthine) 是有效的磷酸二酯酶 (PDE) 抑制剂,腺苷受体拮抗剂,和组蛋白脱乙酰酶 (HDAC) 活化剂。Theophylline (1,3-Dimethylxanthine) 抑制 PDE3 活性,放松气道平滑肌。Theophylline (1,3-Dimethylxanthine) 通过增加 IL-10 和抑制 NF-κ B进入细胞核而具有抗炎活性。Theophylline (1,3-Dimethylxanthine) 诱发细胞凋亡 (apoptosis)。Theophylline (1,3-Dimethylxanthine) 可用于哮喘和慢性阻塞性肺疾病 (COPD) 的研究。
    Theophylline
  • HY-P990007
    Tulisokibart Inhibitor 99.00%
    Tulisokibart (PRA023) 是人源化后的小鼠 IgG1-κ 型抗体,靶向 TNFSF15/TL1A。Tulisokibart 可用于多种炎症/纤维化疾病的研究,例如克罗恩病 (Crohn's Disease, CD) 和溃疡性结肠炎 (ulcerative colitis, UC)。
    Tulisokibart
  • HY-123942
    Diprovocim Agonist 98.35%
    Diprovocim 是一种有效的 TLR1/TLR2 激动剂。Diprovocim 在人 THP-1 细胞中引发完全激动剂活性 (EC50=110 pM)。Diprovocim 刺激小鼠巨噬细胞释放 TNF-α (EC50=1.3 nM)。Diprovocim 激活下游 MAPKNF-κB 信号通路。Diprovocim 在小鼠中显示出很强的佐剂活性,尤其是促进细胞免疫反应。
    Diprovocim
  • HY-13812
    QNZ Inhibitor 99.50%
    QNZ (EVP4593) 强抑制 NF-κB 转录激活和 TNF-α 产生,IC50 分别为 11 和 7 nM。QNZ (EVP4593) 是一种保护神经的钙池操纵的钙通道 (SOC) 抑制剂。
    QNZ
目录号 产品名 / 同用名 种属 表达系统
目录号 产品名 / 同用名 应用 反应物种

Following the binding of TNF to TNF receptors, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I; TNFR2 binds to TRAF1/2 directly to recruit cIAP1/2. Both cIAP1 and cIAP2 are E3 ubiquitin ligases that add K63 linked polyubiquitin chains to RIPK1 and other components of the signaling complex. The ubiquitin ligase activity of the cIAPs is needed to recruit the LUBAC, which adds M1 linked linear polyubiquitin chains to RIPK1. K63 polyubiquitylated RIPK1 recruits TAB2, TAB3 and TAK1, which activate signaling mediated by JNK and p38, as well as the IκB kinase complex. The IKK complex then activates NF-κB signaling, which leads to the transcription of anti-apoptotic factors-such as FLIP and Bcl-XL-that promote cell survival. 

 

The formation of TNFR1 complex IIa and complex IIb depends on non-ubiquitylated RIPK1. For the formation of complex IIa, ubiquitylated RIPK1 in complex I is deubiquitylated by CYLD. This deubiquitylated RIPK1 dissociates from the membrane-bound complex and moves into the cytosol, where it interacts with TRADD, FADD, Pro-caspase 8 and FLIPL to form complex IIa. By contrast, complex IIb is formed when the RIPK1 in complex I is not ubiquitylated owing to conditions that have resulted in the depletion of cIAPs, which normally ubiquitylate RIPK1. This non-ubiquitylated RIPK1 dissociates from complex I, moves into the cytosol, and assembles with FADD, Pro-caspase 8, FLIPL and RIPK3 (but not TRADD) to form complex IIb. For either complex IIa or complex IIb to prevent necroptosis, both RIPK1 and RIPK3 must be inactivated by the cleavage activity of the Pro-caspase 8-FLIPL heterodimer or fully activated caspase 8. The Pro-caspase 8 homodimer generates active Caspase 8, which is released from complex IIa and complex IIb. This active Caspase 8 then carries out cleavage reactions to activate downstream executioner caspases and thus induce classical apoptosis. 

 

Formation of the complex IIc (necrosome) is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs, similar to complex IIa and complex IIb formation. RIPK1 recruits numerous RIPK3 molecules. They come together to form amyloid microfilaments called necrosomes. Activated RIPK3 phosphorylates and recruits MLKL, eventually leading to the formation of a supramolecular protein complex at the plasma membrane and necroptosis [1][2].

 

Reference:
[1]. Brenner D, et al. Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74. 
[2]. Conrad M, et al. Regulated necrosis: disease relevance and therapeutic opportunities.Nat Rev Drug Discov. 2016 May;15(5):348-66. 
 

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.